Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2025 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungen
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to The Report
Fundraising

NuVasive

NuVasive Raises $200M in Convertible Note

1997
Founded
2800+
Employees
7475 Lusk Boulevard, San Diego, CA 92121
Updated June 24, 2024
2 min read

Quick Facts

NuVasive Raises $200M in Convertible Note


NuVasive has successfully raised $200M in a Convertible Note at a $3.5B valuation led by TPG Capital, Goldman Sachs.


Company Overview


NuVasive is a MedTech company headquartered in 7475 Lusk Boulevard, San Diego, CA 92121, founded in 1997 with 2800+ employees.


Minimally disruptive surgical products for spine


Fundraising Details


  • Amount Raised: $200M
  • Round Type: Convertible Note
  • Valuation: $3.5B
  • Date: 2024-06-24
  • Investors: TPG Capital, Goldman Sachs

About NuVasive


Minimally disruptive surgical products for spine The company is positioned in the MedTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 7475 Lusk Boulevard, San Diego, CA 92121
  • Founded: 1997
  • Team Size: 2800+
  • Industry: MedTech

What This Means


This funding round demonstrates strong investor confidence in NuVasive's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The MedTech sector continues to attract significant investment as companies innovate to meet evolving market demands. NuVasive's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $3.5B valuation marks an important milestone for NuVasive, positioning the company among notable players in the MedTech industry.


Looking Ahead


With this new capital, NuVasive is well-positioned to execute on its growth strategy and continue building innovative solutions in the MedTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-06-24. For more information about NuVasive, visit their headquarters at 7475 Lusk Boulevard, San Diego, CA 92121.

Topics

Fundraising(2912)MedTechConvertible NoteNuVasive

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million